ST6GAL1 and neoplasm: Additionally in glioblastoma, ST6Gal1-mediated α2,6-sialylation of crucial receptors such as EGFR and TNFR1 has been shown to enhance tumor-initiating cell (TIC) properties to foster increased self-renewal, therapy resistance, and invasion.